Incidence and treatment costs of severe bacterial infections among people who inject heroin: A cohort study in South London, England
- PMID: 32422537
- PMCID: PMC7301433
- DOI: 10.1016/j.drugalcdep.2020.108057
Incidence and treatment costs of severe bacterial infections among people who inject heroin: A cohort study in South London, England
Abstract
Background: People who inject drugs often get bacterial infections. Few longitudinal studies have reported the incidence and treatment costs of these infections.
Methods: For a cohort of 2335 people who inject heroin entering treatment for drug dependence between 2006 and 2017 in London, England, we reported the rates of hospitalisation or death with primary causes of cutaneous abscess, cellulitis, phlebitis, septicaemia, osteomyelitis, septic arthritis, endocarditis, or necrotising fasciitis. We compared these rates to the general population. We also used NHS reference costs to calculate the cost of admissions.
Results: During a median of 8.0 years of follow-up, 24 % of patients (570/2335) had a severe bacterial infection, most commonly presenting with cutaneous abscesses or cellulitis. Bacterial infections accounted for 13 % of all hospital admissions. The rate was 73 per 1000 person-years (95 % CI 69-77); 50 times the general population, and the rate remained high throughout follow-up. The rate of severe bacterial infections for women was 1.50 (95 % CI 1.32-1.69) times the rate for men. The mean cost per admission was £4980, and we estimate that the annual cost of hospital treatment for people who inject heroin in London is £4.5 million.
Conclusions: People who inject heroin have extreme and long-term risk of severe bacterial infections.
Keywords: Bacterial infections; Drug injection; Heroin; Opiates.
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest MK is employed by the South London and Maudsley NHS Trust (SLaM) as clinical lead for Lambeth Addictions Consortium, which provides treatment for the patients included in this study. JS is a clinician and researcher and has worked extensively on clinical trials and wider research. JS’s employer (King’s College London) receives, unconnected to this specific study but connected to his wider work, project grant support and/or honoraria and/or consultancy payments from government agencies, charitable sources and also from pharmaceutical companies related to funding for clinical trials and research studies (for fuller information see www.kcl.ac.uk/ioppn/depts/addictions/people/hod.aspx).
Figures
References
-
- Advisory Council on the Misuse of Drugs . The Extent to Which Commissioning Structures, the Financial Environment and Wider Changes to Health and Social Welfare Impact on Drug Misuse Treatment and Recovery. 2017. Commissioning impact on drug treatment.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
